SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources…

published 2019-07-31 7 y ago modified 2026-06-16 4 mo ago also EUVD-2007-6719

cvss: 8.8; version 3.0, NVD
cisa kev: Not listed; not in CISA's catalog
epss: 1.3%; EPSS 1.3% chance of exploitation in 30 days, percentile 71%
public exploits: 0; none known

SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.

Patch / fix

fixed in 1

sas sas_drug_development 32drg02

Exploit prediction

1.32% chance of exploitation in the next 30 days, higher than 71% of all scored CVEs (FIRST EPSS, 2026-11-08).

CVSS scores

assigned by	version	score	vector
NVD	3.0	8.8	CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
NVD	2.0	6.5	AV:N/AC:L/Au:S/C:P/I:P/A:P

Classification

Weakness

CWE-20 Improper Input Validation

References

ftp.sas.com /techsup/download/hotfix/drugdev/32drg02/SDD_Release_Notes_32DRG02.pdf
vendor-advisory

Sources

CVE List CVE-2007-6763
NVD CVE-2007-6763

Fencer Vulns keeps one entry per vulnerability: the CVE id wins, then GHSA, and records that alias each other are merged, except that two CVEs always keep separate entries. The same data is available as JSON.

Summary